High Tide to Acquire Majority Stake in Remexian Pharma for €27.2M

High Tide has agreed to acquire 51% of Remexian Pharma GmbH for EUR 27.2M, expanding into the German medical cannabis market. Remexian is a pharmaceutical company with a fully certified EU GDP warehouse and licenses to import medical cannabis from 19 countries, including Canada. The deal is subject to TSX Venture Exchange approval and is expected to close in the coming weeks, valuing the company at EUR53.4M.

High Tide Inc. (Nasdaq: HITI) has announced its entry into the German medical cannabis market through the acquisition of a 51% stake in Remexian Pharma GmbH. The deal, valued at EUR 27.2 million, is subject to TSX Venture Exchange approval and is expected to close in the coming weeks. The transaction will position High Tide as a major player in the German market, which has seen a significant increase in demand and import volumes since the passage of Germany's Consumer Cannabis Act in April 2024 [1].

Remexian Pharma GmbH, founded in 2018, is a leading pharmaceutical company specializing in the importation and wholesale of medical cannabis. With a fully certified EU GDP warehouse and licenses to import from 19 countries, including Canada, Remexian has established itself as a national leader in the German medical cannabis landscape. The company's annualized revenue and Adjusted EBITDA for the six months ended March 2025 were €70 million and €15 million, respectively [1].

High Tide, known for its retail-forward approach, sees significant synergy with Remexian's operational expertise and extensive global reach. The acquisition will allow High Tide to leverage Remexian's established distribution network and deep procurement expertise, particularly in Canada, to expand its presence in Germany. The deal is expected to add approximately C$100 million in topline revenue and significant EBITDA annually, strengthening High Tide's financials and positioning it for growth in the European market [1].

The German medical cannabis market has experienced a surge in demand, with the number of medical cannabis patients rising from an estimated 250,000 to nearly 900,000 over the past year. This has led to a threefold increase in import volumes and annual revenues approaching €1 billion. In the second quarter of 2025, Germany imported a record 43.3 metric tonnes of medical cannabis, with Canada accounting for approximately 36 tonnes in the first six months of 2025 [1].

High Tide's acquisition of Remexian Pharma GmbH underscores the company's strategic expansion into new markets. The transaction highlights High Tide's commitment to providing high-quality medical cannabis at affordable prices, leveraging its Canadian house of brands and global procurement capabilities. As the German market continues to grow, High Tide aims to establish a strong foothold and serve as a springboard into other European markets [1].

References:
[1] https://www.prnewswire.com/news-releases/high-tide-to-become-major-player-in-german-medical-cannabis-market-through-acquisition-of-majority-stake-in-remexian-pharma-gmbh-302530131.html